Diabetic kidney disease (DKD) remains a leading cause of end-stage renal disease, necessitating a comprehensive, multifaceted approach to management. This webinar will explore the evolving paradigm of DKD treatment, focusing on the four key therapeutic pillars: renin-angiotensin system (RAS) blockade, SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists (nsMRAs), and GLP-1 receptor agonists. Experts will discuss the latest clinical evidence, guideline recommendations, and practical strategies for optimizing renal and cardiovascular outcomes in patients with diabetes. Join us for an insightful session on the future of DKD management.